A 54-year-old man developed agranulocytosis and hepatitis seven weeks following institution of thioridazine therapy. Agranulocytosis resolved after 14 days without specific therapy, but the hepatitis resulted in deterioration of liver function, hepatic encephalopathy, and cardiac arrest. Following resuscitation and recovery, myasthenia gravis was diagnosed. To the best of our knowledge, this is the first report in the literature of the simultaneous occurrence of agranulocytosis and hepatitis during thioridazine therapy, and of hepatic coma related to the use of this phenothiazine.
Weiden PL, Buckner CD. Thioridazine ToxicityAgranulocytosis and Hepatitis With Encephalopathy. JAMA. 1973;224(4):518–520. doi:10.1001/jama.1973.03220170044011
Customize your JAMA Network experience by selecting one or more topics from the list below.